为您找到相关结果约86个

你是不是要搜索 期刊FLAURA研究原文 点击跳转

Instant Oncology: FLAURA

FLAURA strikes again: efficacy of osimertinib is independent of PD-L1 expression Comment

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA

Freeing the Competition: Will Aumolertinib (AENEAS) Have a Fighting Chance Against Osimertinib (FLAURA

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA

Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA

Osimertinib Long-Term Tolerability in Patients with EGFRm NSCLC Enrolled in the AURA Program or FLAURA

Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated

Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA

Final Overall Survival Results from the FLAURA Trial: a Phase III Study on Osimertinib in EGFR-Mutated

Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA

DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA

PD-L1 Expression in Untreated EGFRm Advanced NSCLC and Response to Osimertinib and SoC EGFR-TKIs in the FLAURA

standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA

Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall

为您找到相关结果约86个

共86条页码: 1/6页15条/页